ReviewFrontiers in neurology2022
The amyloid imaging for the prevention of Alzheimer's disease consortium: A European collaboration with global impact.
Review in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 21 citations in OpenAlex.
- Decreased amyloid-related structure-function coupling in preclinical Alzheimer's disease.Communications medicine · 2026Article
- Cortical gray-white matter contrast alterations precede amyloid-β positivity and macrostructural changes in older adults without dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Self-reported sleep quality and longitudinal amyloid burden in clinically unimpaired adults from the AMYPAD PNHS study.Alzheimer's research & therapy · 2026Article
- AI-enhanced Centiloid quantification of amyloid PET images.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Blood pressure and Alzheimer's disease biomarkers in cognitively unimpaired adults: a multicenter study.The journal of prevention of Alzheimer's disease · 2025Observational
- Cortical thickness subtypes in cognitively unimpaired individuals: Differential network and transcriptomic vulnerability to cortical thinning.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Revisiting Centiloids using AI.Research square · 2025Article
- Use of Amyloid Positron-Emission Tomography to Diagnose Alzheimer's Disease in Clinical Practice in South Korea: Expert Recommendations.Journal of clinical neurology (Seoul, Korea) · 2025Review
- Quantification Supports Amyloid PET Visual Assessment of Challenging Cases: Results from the AMYPAD Diagnostic and Patient Management Study.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Investigating the effects of Ginkgo biloba leaf extract on cognitive function in Alzheimer's disease.CNS neuroscience & therapeutics · 2024Article
- Digital remote assessment of speech acoustics in cognitively unimpaired adults: feasibility, reliability and associations with amyloid pathology.Alzheimer's research & therapy · 2024Article
- Amyloid-PET imaging predicts functional decline in clinically normal individuals.Alzheimer's research & therapy · 2024Article
- Investigating reliable amyloid accumulation in Centiloids: Results from the AMYPAD Prognostic and Natural History Study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- From Innovator Result-driven to Multi-actor Impact-oriented Public-Private Partnerships: Integrating the Patient Perspective.Handbook of experimental pharmacology · 2024Review
- Plasma pTau181 and pTau217 predict asymptomatic amyloid accumulation equally well as amyloid PET.Brain communications · 2024Article
- The preservation of right cingulum fibers in subjective cognitive decline of preclinical phase of Alzheimer's disease.Frontiers in aging neuroscience · 2023Article
- Data sharing in neurodegenerative disease research: challenges and learnings from the innovative medicines initiative public-private partnership model.Frontiers in neurology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors at 17 institutions in 9 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Amyloid-β (Aβ) accumulation is considered the earliest pathological change in Alzheimer's disease (AD). The Amyloid Imaging to Prevent Alzheimer's Disease (AMYPAD) consortium is a collaborative European framework across European Federation of Pharmaceutical Industries Associations (EFPIA), academic, and 'Small and Medium-sized enterprises' (SME) partners aiming to provide evidence on the clinical utility and cost-effectiveness of Positron Emission Tomography (PET) imaging in diagnostic work-up of AD and to support clinical trial design by developing optimal quantitative methodology in an early AD population. The AMYPAD studies: In the Diagnostic and Patient Management Study (DPMS), 844 participants from eight centres across three clinical subgroups (245 subjective cognitive decline, 342 mild cognitive impairment, and 258 dementia) were included. The Prognostic and Natural History Study (PNHS) recruited pre-dementia subjects across 11 European parent cohorts (PCs). Approximately 1600 unique subjects with historical and prospective data were collected within this study. PET acquisition with [ Results: AMYPAD has significantly contributed to the AD field by furthering our understanding of amyloid deposition in the brain and the optimal methodology to measure this process. Main contributions so far include the validation of the dual-time window acquisition protocol to derive the fully quantitative non-displaceable binding potential (BP Future steps: The AMYPAD consortium has succeeded in recruiting and following a large number of prospective subjects and setting up a collaborative framework to integrate data across European PCs. Efforts are currently ongoing in collaboration with ARIDHIA and ADDI to harmonize, integrate, and curate all available clinical data from the PNHS PCs, which will become openly accessible to the wider scientific community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.